138 related articles for article (PubMed ID: 35174659)
1. Transgenic HepaRG cells expressing CYP2D6 as an improved model of primary human hepatocytes.
Okuyama S; Mine A; Nakamura T; Ohasi Y; Seto M; Tada M
Pharmacol Res Perspect; 2022 Apr; 10(2):e00939. PubMed ID: 35174659
[TBL] [Abstract][Full Text] [Related]
2. Dual-color fluorescence imaging to monitor CYP3A4 and CYP3A7 expression in human hepatic carcinoma HepG2 and HepaRG cells.
Tsuji S; Kawamura F; Kubiura M; Hayashi A; Ohbayashi T; Kazuki Y; Chesné C; Oshimura M; Tada M
PLoS One; 2014; 9(8):e104123. PubMed ID: 25101946
[TBL] [Abstract][Full Text] [Related]
3. A two-dimensional multiwell cell culture method for the production of CYP3A4-expressing hepatocyte-like cells from HepaRG cells.
Ooeda K; Kubiura-Ichimaru M; Tsuji S; Okuyama S; Yamashita M; Mine A; Kawamura F; Ueyama T; Tada M
Pharmacol Res Perspect; 2020 Oct; 8(5):e00652. PubMed ID: 32955797
[TBL] [Abstract][Full Text] [Related]
4. HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro.
Lübberstedt M; Müller-Vieira U; Mayer M; Biemel KM; Knöspel F; Knobeloch D; Nüssler AK; Gerlach JC; Zeilinger K
J Pharmacol Toxicol Methods; 2011; 63(1):59-68. PubMed ID: 20460162
[TBL] [Abstract][Full Text] [Related]
5. Fluorometric evaluation of CYP3A4 expression using improved transgenic HepaRG cells carrying a dual-colour reporter for CYP3A4 and CYP3A7.
Ueyama T; Tsuji S; Sugiyama T; Tada M
Sci Rep; 2017 Jun; 7(1):2874. PubMed ID: 28588200
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies.
Kanebratt KP; Andersson TB
Drug Metab Dispos; 2008 Jul; 36(7):1444-52. PubMed ID: 18385292
[TBL] [Abstract][Full Text] [Related]
7. HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans.
Kanebratt KP; Andersson TB
Drug Metab Dispos; 2008 Jan; 36(1):137-45. PubMed ID: 17954527
[TBL] [Abstract][Full Text] [Related]
8. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics.
Guillouzo A; Corlu A; Aninat C; Glaise D; Morel F; Guguen-Guillouzo C
Chem Biol Interact; 2007 May; 168(1):66-73. PubMed ID: 17241619
[TBL] [Abstract][Full Text] [Related]
9. Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5.
Yoshida K; Sun B; Zhang L; Zhao P; Abernethy DR; Nolin TD; Rostami-Hodjegan A; Zineh I; Huang SM
Clin Pharmacol Ther; 2016 Jul; 100(1):75-87. PubMed ID: 26800425
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG, Cryopreserved Human Hepatocytes, and HepG2 Cell Cultures.
Yokoyama Y; Sasaki Y; Terasaki N; Kawataki T; Takekawa K; Iwase Y; Shimizu T; Sanoh S; Ohta S
Biol Pharm Bull; 2018 May; 41(5):722-732. PubMed ID: 29445054
[TBL] [Abstract][Full Text] [Related]
11. 4-Fluoromethamphetamine (4-FMA) induces in vitro hepatotoxicity mediated by CYP2E1, CYP2D6, and CYP3A4 metabolism.
Roque Bravo R; Carmo H; Valente MJ; Silva JP; Carvalho F; Bastos ML; Dias da Silva D
Toxicology; 2021 Nov; 463():152988. PubMed ID: 34655687
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Normalization Methods To Predict CYP3A4 Induction in Six Fully Characterized Cryopreserved Human Hepatocyte Preparations and HepaRG Cells.
Vermet H; Raoust N; Ngo R; Esserméant L; Klieber S; Fabre G; Boulenc X
Drug Metab Dispos; 2016 Jan; 44(1):50-60. PubMed ID: 26467767
[TBL] [Abstract][Full Text] [Related]
13. Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes.
Han SY; Zhao HY; Zhou N; Zhou F; Li PP
J Ethnopharmacol; 2014; 151(1):210-7. PubMed ID: 24157377
[TBL] [Abstract][Full Text] [Related]
14. Exploration of components and mechanisms of Polygoni Multiflori Radix-induced hepatotoxicity using siRNA -mediated CYP3A4 or UGT1A1 knockdown liver cells.
Hu YH; Li DK; Quan ZY; Wang CY; Zhou M; Sun ZX
J Ethnopharmacol; 2021 Apr; 270():113845. PubMed ID: 33485974
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 1A1/2, 2B6 and 3A4 HepaRG Cell-Based Biosensors to Monitor Hepatocyte Differentiation, Drug Metabolism and Toxicity.
Vlach M; Quesnot N; Dubois-Pot-Schneider H; Ribault C; Verres Y; Petitjean K; Rauch C; Morel F; Robin MA; Corlu A; Loyer P
Sensors (Basel); 2019 May; 19(10):. PubMed ID: 31096615
[TBL] [Abstract][Full Text] [Related]
16. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells.
Aninat C; Piton A; Glaise D; Le Charpentier T; Langouët S; Morel F; Guguen-Guillouzo C; Guillouzo A
Drug Metab Dispos; 2006 Jan; 34(1):75-83. PubMed ID: 16204462
[TBL] [Abstract][Full Text] [Related]
17. HepaRG cells as human-relevant in vitro model to study the effects of inflammatory stimuli on cytochrome P450 isoenzymes.
Rubin K; Janefeldt A; Andersson L; Berke Z; Grime K; Andersson TB
Drug Metab Dispos; 2015 Jan; 43(1):119-25. PubMed ID: 25371393
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA hsa-miR-370-3p suppresses the expression and induction of CYP2D6 by facilitating mRNA degradation.
Zeng L; Chen Y; Wang Y; Yu LR; Knox B; Chen J; Shi T; Chen S; Ren Z; Guo L; Wu Y; Liu D; Huang K; Tong W; Yu D; Ning B
Biochem Pharmacol; 2017 Sep; 140():139-149. PubMed ID: 28552654
[TBL] [Abstract][Full Text] [Related]
19. The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients.
van der Weide K; van der Weide J
J Clin Psychopharmacol; 2015 Jun; 35(3):228-36. PubMed ID: 25868121
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of in vitro cytochrome P450 induction and inhibition activity of deoxyelephantopin, a sesquiterpene lactone from Elephantopus scaber L.
Koe XF; Lim EL; Seah TC; Amanah A; Wahab HA; Adenan MI; Sulaiman SF; Tan ML
Food Chem Toxicol; 2013 Oct; 60():98-108. PubMed ID: 23876819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
